Table 1.
Clinicopathological Characteristics of Enrolled NSCLC Patients Stratified by SII
| Variables | Categories | Overall | SII<889 | SII≥889 | P |
|---|---|---|---|---|---|
| Number (n, %) | 353 | 190 (53.8%) | 163 (46.2%) | ||
| Gender (n, %) | |||||
| Male | 227 (64.3%) | 108 (56.8%) | 119 (73.0%) | 0.002 | |
| Female | 126 (34.7%) | 82 (43.2%) | 44 (27.0%) | ||
| Age (years, mean±SD) | Year | 58±7.48 | 58.65±6.55 | 59.07±8.46 | 0.61 |
| Tobacco (n, %) | |||||
| Never | 178 (50.6%) | 107 (56.6%) | 71 (43.6%) | 0.04 | |
| Former | 17 (4.9%) | 7 (3.7%) | 10 (6.1%) | ||
| Current | 158 (44.5%) | 76 (39.7%) | 82 (50.3%) | ||
| Hypertension (n, %) | |||||
| Yes | 50 (14.2%) | 30 (15.8%) | 20 (12.3%) | 0.34 | |
| No | 303 (85.8%) | 160 (84.2%) | 143 (87.7%) | ||
| Diabetes (n, %) | |||||
| Yes | 11 (3.1%) | 5 (2.6%) | 6 (3.7%) | 0.57 | |
| No | 342 (96.9%) | 185 (97.4%) | 157 (96.3%) | ||
| Education (n, %) | |||||
| ≤12 years/completed high school | 329 (93.2%) | 179 (94.2%) | 150 (92.0%) | 0.42 | |
| >12 years | 24 (6.8%) | 11 (5.8%) | 13 (8.0%) | ||
| ECOG (n, %) | |||||
| 0 | 323 (91.5%) | 174 (91.6%) | 149 (91.4%) | 0.96 | |
| >0 | 30 (8.5%) | 16 (8.4%) | 14 (8.6%) | ||
| Tumor types (n, %) | |||||
| LUSC | 172 (48.7%) | 79 (41.6%) | 93 (57.1%) | 0.004 | |
| LUAD | 111 (58.4%) | 70 (42.9%) | |||
| Tumor grade (n, %) | |||||
| Highly differentiated | 53 (15.0%) | 22 (11.6%) | 31 (19.0%) | 0.72 | |
| Moderately differentiated | 64 (18.1%) | 31 (16.3%) | 33 (20.2%) | ||
| Poorly differentiated | 236 (66.9%) | 137 (72.1%) | 99 (60.8%) | ||
| Tumor size (median, IQR) | CM | 4.00 [3.00, 5.40] | 3.95 [3.00, 5.30] | 4.10 [2.95, 5.55] | 0.55 |
| Lymph node (n, %) | |||||
| N0 | 137 (38.8%) | 92 (48.4%) | 45 (27.6%) | <0.001 | |
| N1–N3 | 216 (61.2%) | 98 (51.6%) | 118 (72.4%) | ||
| Stage (n, %) | |||||
| I | 78 (22.1%) | 58 (30.5%) | 20 (12.3%) | <0.001 | |
| II | 103 (29.2%) | 76 (40.0%) | 27 (16.6%) | ||
| III | 76 (21.5%) | 24 (12.6%) | 52 (31.9%) | ||
| IV | 96 (27.2%) | 32 (16.8%) | 64 (39.3%) | ||
| Metastasis (n, %) | |||||
| One organ | 68 (19.2%) | 28 (87.5%) | 40 (62.5%) | 0.02 | |
| Two organs or more organs | 28 (7.9%) | 4 (12.5%) | 24 (27.5%) | ||
| Therapy (n, %) | |||||
| SC | 187 (52.9%) | 125 (65.8%) | 62 (38.0%) | <0.001 | |
| C | 166 (47.1%) | 65 (34.2%) | 101 (62.0%) | ||
| ACCI (median, IQR) | 4 [3, 7] | 4 [3, 6] | 6 [4, 8] | <0.001 | |
| ACCI (n, %) | |||||
| <5 | 177 (50.1%) | 115 (60.5%) | 62 (38.0%) | <0.001 | |
| ≥5 | 176 (49.9%) | 75 (39.5%) | 101 (62.0%) |
Abbreviations: SII, systemic immune-inflammation index; ECOG score, eastern cooperative oncology group score; ACCI, age-adjusted Charlson comorbidity index; IQR, interquartile range; LUSC, squamous cell lung cancer; LUAD, lung adenocarcinoma; SC, surgical resection with adjuvant chemotherapy; C, chemotherapy without surgery.